CoChat
Sign Up
Cited by 28Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Neuropathology of Alzheimer’s Disease

Open access
Schultz, Christian, Del Tredici, Kelly, Braak, Heiko·2004·Alzheimer’s Disease
DOI 10.1007/978-1-59259-661-4_2
Open this paper in CoChat — free account

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative and dementing disorder that can be detected clinically only in its end phase. AD is the most widespread type of dementia and affects about 10% of individuals older than 65 years and about 40% of individuals older than 80 years of age (1,2). The earliest sign of AD is a subtle decline in memory functions in a state of clear consciousness. Mental capabilities gradually worsen and personality changes appear, followed by deterioration of language functions, impairment of visuospatial tasks, and, in the disease’s final stages, dysfunction of the motor system in the form of a hypokinetic-hypertonic syndrome.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-1-59259-661-4_2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized.

    “Alzheimer’s disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized.”

    From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [2]

  • Alzheimer's disease is the most common cause of dementia globally.

    “Alzheimer’s disease is the most common cause of dementia globally.”

    From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [2]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. McKhann, G. et al.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944. · DOI · Paper page
  2. Beyreuther, K.; Masters, C.L.: Amyloid precursor protein (APP) and beta amyloid-4 amyloid in the etiology of Alzheimer’s disease: precursor product relationships in the derangement of neuronal function. Brain Pathol 1991; 1: 241–252. · DOI · Paper page
  3. Selkoe, D.J.: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741–766. · DOI · Paper page
  4. Arriagada, P.V. et al.: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992; 42: 631–639. · DOI · Paper page
  5. Esiri, M.M. et al.: Aging and dementia. In: Graham, D.L.; Lantos, P.I. (eds.): Greenfield’s neuropathology. Arnold, London, 1997: 153–234.
  6. Feany, M.B., et al.: Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 1996; 40: 139–148. · DOI
  7. Ikeda, K. et al.: Glial tau pathology in neurodegenerative diseases: their nature and comparison with neuronal tangles. Neurobiol Aging 1998; 19: S85 - S91. · DOI
  8. Hutton, M. et al.: Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702–705. · DOI · Paper page
  9. Bancher, C. et al.: Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer’s and Parkinson’s disease. Neurosci Lett 1993; 162: 179–182. · DOI
  10. Price, J.L.; Morris, J.C.: Tangles and plaques in non-demented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999; 45: 358–368. · DOI
  11. Riley, K.P. et al.: Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 2002; 51: 567–577. · DOI
  12. Kemper, T.L.: Senile dementia: a focal disease in the temporal lobe. In: Nandy, E. (ed.): Senile dementia: a biomedical approach. Elsevier, Amsterdam, 1978: 105–113.
  13. van Hoesen, G.W.; Hyman, B.T.: Hippocampal formation: anatomy and the patterns of pathology in Alzheimer’s disease. Progr Brain Res 1990; 83: 445–457. · DOI
  14. van Hoesen, G.W. et al.: Entorhinal cortex pathology in Alzheimer’s disease. Hippocampus 1991; 1: 1–8. · DOI · Paper page
  15. Braak, H.; Braak, E.: Architectonics as seen by lipofuscin stains. In: Peters, A.; Jones, E.G. (eds.): Cerebral cortex. Vol. 1: Cellular organization of the cerebral cortex. Plenum Press, New York, 1984: 59–104.
  16. Braak, H.; Braak, E.: Temporal sequence of Alzheimer’s disease-related pathology. In: Peters, A.; Morrison, J.H. (eds.): Cerebral cortex. Vol. 14, Neurodegenerative and age-related changes in structure and function of the cerebral cortex. KluwerPlenum, New York, 1999: 475–512. · DOI
  17. Goedert, M.: Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 1993; 16: 460–465. · DOI
  18. Iqbal, K. et al.: Mechanism of neurofibrillary degeneration in Alzheimer’s disease. Molec Neurobiol 1994; 9: 119–123. · DOI
  19. Mandelkow, E.; Mandelkow, E.M.: Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995; 7: 72–81. · DOI · Paper page
  20. Bancher, C. et al.: Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 1989; 477: 90–99. · DOI · Paper page
  21. Braak, E. et al.: A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 1994; 87: 554–567. · DOI
  22. Hyman, B.T.; Gomez-Isla, T.: Alzheimer’s disease is a laminar, regional, and neural system specific disease, not a global brain disease. Neurobiol Aging 1994; 15: 353–354. · DOI
  23. Braak, H.; Braak, E.: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351–357. · DOI · Paper page
  24. Hyman, B.T.; Trojanowski, J.Q.: Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institutes of Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 1095–1097. · DOI · Paper page
  25. Hyman, B.T.: New neuropathological criteria for Alzheimer’s disease. Arch Neurol 1998; 55: 1174–1176. · DOI
  26. Delacourte, A. et al.: The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 2000; 52: 1158–1165. · DOI · Paper page
  27. Delacourte, A. et al.: Non-overlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 2002; 59: 398–407. · DOI
  28. Jellinger, K., et al.: Alzheimer lesions in the entorhinal region and isocortex in Parkinson’s and Alzheimer’s diseases. Ann NY Acad Sci 1991; 640: 203–209. · DOI
  29. Duyckaerts, C. et al.: Diagnosis and staging of Alzheimer’s disease in a prospective study involving aged individuals. Neurobiol Aging 1994 (suppl. 1); 15: 140–141.
  30. Dickson, D.W. et al.: Identification of normal and pathological aging in prospectively studied non-demented elderly humans. Neurobiol Aging 1991; 13: 179–189. · DOI · Paper page
  31. Ohm, T.G. et al.: Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 1995; 64: 209–217. · DOI
  32. Thal, D.R. et al.: Sequence of A beta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000; 59: 733–748. · DOI · Paper page
  33. Thal, D.R. et al.: Phases of A beta-deposition in the human brain and its relevance for the Development of AD. Neurology 2002; 58: 1791–1800. · DOI · Paper page
  34. Braak, H.; Braak, E.: Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996; 92: 197–201. · DOI · Paper page
  35. Braak, H.; Braak, E.: Pathology of Alzheimer’s disease. In: Calne, D.B. (ed.): Neurodegenerative diseases. Saunders, Philadelphia, 1994: 585–613.
  36. Hock, B.7.; Lamb, B.T.: Transgenic mouse models of Alzheimer’s disease. Trends Genet 2001; 17: S7 - S12. · DOI
  37. Ishihara, T. et al.: Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol 2001; 158: 555–562. · DOI
  38. Götz, J. et al.: Formation of neurofibrillary tangles in P3011 tau transgenic mice induced byAbeta 42 fibrils. Science 2001; 293: 1491–1495. · DOI · Paper page
  39. Lewis, J. et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001); 293: 1487–1491. · DOI · Paper page
  40. Schultz, C. et al.: Filamentous tau pathology in nerve cells, astrocytes, and oligodendrocytes of aged baboons. J Neuropathol Exp Neurol 2000; 59: 39–52. · DOI
  41. Schultz, C. et al.: Age-related progression of tau pathology in brains of baboons. Neurobiol Aging 2000; 21: 905–912. · DOI
  42. Schultz, C. et al.: The brain of the aging baboon: a non-human primate model for neuronal and glial tau pathology. In: Erwin, 7.M.; Hof, P.R. (eds.): Aging in non-human primates. Interdiscipl Top Gerontol, Vol. 31. Karger, Basel, 2002: 118–129. · DOI

Cited by

Sorted by citations

Metadata

Authors
Schultz, C., Del Tredici, K., & Braak, H.
ORCID
Venue
Alzheimer’s Disease
Publisher
Humana Press
Published
2004
Pages
21-31
DOI
10.1007/978-1-59259-661-4_2
OpenAlex
W2218206454
Cited by
28
References
5
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 3
FWCI
1.39
Type
book chapter
Language
en
Open access
Licence
Locations
  • Humana Press eBooks (publishedVersion, cc-by)
  • Humana Press eBooks (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, neuropathology, neurodegeneration, dementia, memory decline, cognitive impairment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review